AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04542226
Drug: Polyoxidonium
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)
Trial: NCT02055456
Drug: Nandrolone Decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01058083
Drug: BMS-770767
RxNorm normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active, Oral, 15 mg, Daily, 28 days
Trial: NCT01058083
Drug: BMS-770767
RxNorm normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active, Oral, 50 mg, Daily, 28 days
Trial: NCT01058083
Drug: BMS-770767
RxNorm normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active, Oral, 150 mg, Daily, 28 days
Trial: NCT01058083
Drug: BMS-770767
RxNorm normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active, Oral, 50 mg BID, Daily, 28 days
Trial: NCT00056810
Drug: 4-aminopyridine (4-AP)
RxNorm normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00708305
Drug: Sodium Fluoride (NaF)
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
Trial: NCT03491748
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT00624325
Drug: interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 MU daily continuously subcutaneous
Trial: NCT00624325
Drug: interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 MU daily continuously subcutaneous
Trial: NCT00624325
Drug: interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 MU daily continuously subcutaneous
Trial: NCT00507806
Drug: perflutren lipid microsphere
RxNorm normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03512197
Drug: Midostaurin
RxNorm normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Midostaurin was provided as 25 mg capsules 8PC, was supplied as double-blind in blister packs and taken orally.
Trial: NCT03842436
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Truvada prescribed with digital pills for PrEP
Trial: NCT00231764
Drug: daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02842983
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conventional management plus esmolol infusion
Trial: NCT00723424
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg dose
Trial: NCT04524728
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablets
Trial: NCT04524728
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT04524728
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intramuscolar injections
Trial: NCT00311246
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
Trial: NCT01466790
Drug: PSI-7977 (GS7977)
RxNorm normalized name: psi-Norephedrine
DrugBank: Cathine (DB01486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
Trial: NCT01466790
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
Trial: NCT00002740
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002740
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002740
Drug: mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002740
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02145169
Drug: Inhaled Nitrous Oxide
RxNorm normalized name: nitrous oxide Inhalant Product
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
Trial: NCT01670071
Drug: Paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
Trial: NCT01670071
Drug: Risperidone immediate-release
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
Trial: NCT03438240
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%
Trial: NCT03438240
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Plus 50 µg dexmedetomidine
Trial: NCT02419729
Drug: Estrogen
RxNorm normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical estrogen cream treatment: Estriol 1mg daily.
Trial: NCT02386839
Drug: rhIGF-1/rhIGFBP-3
DrugBank: rhIGFBP-3 (DB05897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study.
Trial: NCT01275196
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01275196
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01027364
Drug: Factor IX (rFIXFc)
RxNorm normalized name: factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00985543
Drug: lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
Trial: NCT00811421
Drug: Sulphadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
Trial: NCT00811421
Drug: Mefloquine (full dose)
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
Trial: NCT00811421
Drug: Mefloquine (split dose)
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
Trial: NCT00811421
Drug: mefloquine
RxNorm normalized name: Mefloquine
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
Trial: NCT00495092
Drug: Biperiden
RxNorm normalized name: Biperiden
DrugBank: Biperiden (DB00810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biperiden 2-4 mg/d p.o.
Trial: NCT00204308
Drug: Combination tenofovir-emtricitabine
RxNorm normalized name: emtricitabine / tenofovir disoproxil
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
Trial: NCT04205929
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
Trial: NCT01529671
Drug: PF-05089771
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05089771 will be dosed as a suspension twice daily (BID)
Trial: NCT01529671
Drug: PF-05089771
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05089771 will be dosed as a suspension BID
Trial: NCT00089895
Drug: Eptifibatide (Integrilin)
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG \[coronary artery bypass graft\]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
Trial: NCT03835637
Drug: ORIC-101
RxNorm normalized name: Oriconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule or oral suspension
Trial: NCT01040286
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5mg
Trial: NCT00002499
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002499
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002499
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002499
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002499
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002499
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04412252
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg tofacitinib administered as two 5 mg tablets or solution taken orally twice daily for 14 days
Trial: NCT00791804
Drug: AeroLEF
RxNorm normalized name: AeroLEF
DrugBank: AeroLEF (DB05000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~* for nebulized administration as required by the patient.~* Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl.
Trial: NCT02714608
Drug: Ginsenoside H dripping pills
RxNorm normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
Trial: NCT02888067
Drug: Rocuronium bromide 0.5 mg/kg
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate neuromuscular blockade with rocuronium bromide
Trial: NCT02888067
Drug: Rocuronium bromide 1.0 mg/kg
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deep neuromuscular blockade with rocuronium bromide
Trial: NCT02888067
Drug: Sugammadex sodium 2 mg/kg
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Reversal with sugammadex sodium
Trial: NCT02888067
Drug: Sugammadex sodium 4 mg/kg
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Reversal with sugammadex sodium
Trial: NCT01860014
Drug: Poractant alfa
RxNorm normalized name: Poractant alfa
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
Trial: NCT01860014
Drug: Beractant
RxNorm normalized name: Beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
Trial: NCT01291316
Drug: Clonazepam
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clonazepam, 1 mg, single oral dose
Trial: NCT01291316
Drug: Tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolterodine 1,37mg, single oral dose
Trial: NCT01291316
Drug: clobazam
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clobazam 20 mg, single oral dose
Trial: NCT02222519
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6mg/kg iv single dose
Trial: NCT01885260
Drug: ISIS-GCGRRx - Dose Level 1
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 doses on alternate days during the first week and then once weekly for 12 weeks
Trial: NCT01885260
Drug: ISIS-GCGRRx - Dose Level 2
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 doses on alternate days during the first week and then once weekly for 12 weeks
Trial: NCT00702182
Drug: Vinorelbine (Navelbine)
RxNorm normalized name: vinorelbine Injection [Navelbine]
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
Trial: NCT00702182
Drug: Vinorelbine (Navelbine)
RxNorm normalized name: vinorelbine Injection [Navelbine]
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronomic Schedule Oral Vinorelbine 3 times a week
Trial: NCT00702182
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily Oral Erlotinib 100 mg
Trial: NCT01447849
Drug: lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24mcg twice a day (BID) 1 week
Trial: NCT00002502
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002502
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03560245
Drug: Bryostatin
RxNorm normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
Trial: NCT03093740
Drug: Zepatier
RxNorm normalized name: Zepatier
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Based on negative viral resistance testing of the donor treatment will be Zepatier
Trial: NCT03093740
Drug: Zepatier plus Sofosbuvir
RxNorm normalized name: Zepatier
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir
Trial: NCT02400437
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
Trial: NCT02400437
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
Trial: NCT02400437
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Doses given on Day 1 of induction and maintenance cycles.
Trial: NCT00004202
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004202
Drug: efaproxiral
RxNorm normalized name: EFAPROXIRAL
DrugBank: Efaproxiral (DB08486)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004202
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03671733
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
Trial: NCT03671733
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
Trial: NCT03671733
Drug: Exenatide Microspheres for Injection
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg injection once weekly for 12 weeks.
Trial: NCT02714608
Drug: Ginsenoside H dripping pills+Placebo
RxNorm normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
Trial: NCT03428126
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation and Dose Expansion Dose: 1500 mg by vein every 4 weeks in a 28 day cycle.
Trial: NCT03428126
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose Escalation Starting Dose: 2mg by mouth daily in a 28 day cycle.~Dose Expansion Dose: MTD from Dose Escalation.
Trial: NCT02611830
Drug: Vedolizumab 300 mg IV
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab intravenous infusion
Trial: NCT00101998
Drug: alvimopan
RxNorm normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02611830
Drug: Vedolizumab 108 mg SC
RxNorm normalized name: vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab subcutaneous injection
Trial: NCT00412035
Drug: Botulinum toxin A injection
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 10 units per kilo to maximum of 400 units
Trial: NCT00412035
Drug: saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 units per kilo to maximum of 400 units
Trial: NCT01569035
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 mg warfarin oral tablet for 2 to 3 weeks
Trial: NCT02215733
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03581877
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As stated before, low dose r-tpa will be administered through a peripheral vein for PLST.
Trial: NCT02380508
Drug: BCG SSI
RxNorm normalized name: BCG SSI
DrugBank: Bacillus calmette-guerin substrain danish 1331 live antigen (DB12386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection
Trial: NCT02380508
Drug: BCG Sii
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradermal injection
Trial: NCT02120664
Drug: Florbetapir (18F)
RxNorm normalized name: florbetapir (18F)
DrugBank: Florbetapir F-18 (DB09149)
FDA approved: yes
EMA approved: no
PMDA approved: no